Ahead of Robert F. Kennedy Jr.’s confirmation hearings, New York Times Opinion invited experts and leaders across disciplines and ideologies to share questions they believe Mr. Kennedy must answer before serving in a role that oversees a $1.7 trillion budget and wields enormous influence over drug approvals, public health and the nation’s research agenda.

M. Anthony Mills, a senior fellow at AEI and director of its Center for Technology, Science and Energy, contributed the following question:

11. Following the Supreme Court’s Dobbs decision, federal health agencies have found themselves at the center of the debate around abortion and contraception access. Do you believe agencies under your purview should restrict access to drugs such as mifepristone in states with laws limiting access to abortion? — M. Anthony Mills, director of the Center for Technology, Science and Energy at the American Enterprise Institute

Read the full list of questions here.